Pharmacokinetic/LDL‐C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies

• Main Authors: Shuling Yan (Author), Xia Zhao (Author), Qiushi Xie (Author), Weijuan Du (Author), Qingyang Ma (Author), Tongkang Zhu (Author), Huan Deng (Author), Lei Qian (Author), Shirui Zheng (Author), Yimin Cui (Author)
• Format: Book
• Published: Wiley, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Tafolecimab, a novel fully human monoclonal antibody targeting PCSK9, has been assessed in Chinese healthy volunteers and patients with hypercholesterolemia. This analysis is to develop and qualify a population pharmacokinetics (PopPKs)/LDL‐C model to characterize tafolecimab PK and LDL‐C p...